Altimmune, Inc. (ALT) is a pre-revenue biotech whose valuation rests almost entirely on the clinical and commercial potential of pemvidutide, its lead GLP-1/glucagon dual receptor agonist. Seven current, attributable price targets were reviewed, spanning roughly $10 to $28. The arithmetic mean of these targets is $17.00, which serves as the central target used throughout this article. For context, S&P Global's published average of about $17.11 across ten analysts is broadly consistent with this figure.
The range is exceptionally wide, which is typical of early-stage biotech where different analysts apply different probability-of-success assumptions. Recent revisions have generally trended lower as firms adjusted for share-count dilution and moderated revenue expectations: Evercore ISI lowered its target to $17 from $18 (September 2026), H.C. Wainwright to $20 from $25, and Citizens JMP to $11 from $14. Barclays and H.C. Wainwright each hold $20 targets, while Jefferies maintains the highest at $28. Notably, William Blair and Truist publish ratings but no price target, and at least one research shop carries a sell-equivalent view, underscoring that the analyst community is not unanimous.
ALT last traded around $2.04, near the lower end of its 52-week range of roughly $2.02 to $6.44. Reaching $17 implies upside of approximately 730%, which must be characterized as a very large move by any standard. Such a move would require not merely favorable data but a fundamental repricing of the company's entire risk profile — something that in biotech typically occurs only through pivotal trial success, a partnership, or a takeover.
The path toward the target would depend heavily on pemvidutide's Phase 3 MASH program (the PERFORMA trial), whose 52-week topline readout is not expected until 2029, and on progress in AUD. Positive Phase 2 RECLAIM results in alcohol use disorder, reported in mid-2026, showed statistically significant improvements across endpoints and validated a potential second indication. Still, with negligible revenue and an EPS (earnings per share) that remains negative, the stock's valuation is driven by future expectations rather than current fundamentals.
Several verified factors could support a higher valuation. Pemvidutide's differentiation — particularly lean-mass preservation and liver-fat reduction relative to competing GLP-1 therapies — is a recurring theme in bullish research. Positive Phase 2 RECLAIM data in AUD expanded the potential addressable market beyond MASH, and Barclays described the readout as highlighting a meaningful opportunity. The company's cash position (roughly $326 million in recent filings) and management's stated runway through the MASH 52-week readout reduce near-term financing overhang, a point H.C. Wainwright cited as "a clear net positive." Insiders, including the CFO and directors, have also been purchasers of shares in 2026.
The obstacles are substantial. Altimmune remains pre-commercial, with revenue in the tens of thousands of dollars against operating losses in the tens of millions annually. Advancing a Phase 3 AUD program may require additional capital that is not yet secured. Pemvidutide also faces gastrointestinal tolerability challenges and historically elevated discontinuation rates, which could constrain dosing or adherence. Competition from Novo Nordisk and Eli Lilly, both far larger and better capitalized, creates enrollment and commercialization headwinds. Finally, the extreme dispersion in analyst targets — from $10 to $28 — reflects genuine uncertainty about the probability of clinical and regulatory success.
From a technical standpoint, ALT sits near its 52-week low of roughly $2.02, which functions as a key support level. A breakdown below this area would signal further downside risk. The 50-day and 200-day simple moving averages both sit near $2.99, meaning the stock trades well below its longer-term trend and would need to reclaim that zone before any sustained recovery could be considered. The $6.44 52-week high represents the nearest major overhead resistance level, followed by psychological price levels well above it. The stock's beta near 0.06 indicates it has moved largely on company-specific, clinical news rather than broad market direction.
Analyst price targets for ALT generally reflect a roughly 12-month research horizon, though the wide dispersion in targets suggests analysts are effectively underwriting events that lie years out, such as the 2029 MASH readout. Nearer-term, investors should watch the company's earnings report (expected in November 2026), any updates on the Phase 3 PERFORMA trial enrollment and the AUD program, financing or partnership announcements, and further analyst target revisions. Regulatory milestones and competitive data from larger GLP-1 developers are also relevant to the long-term thesis.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a highly volatile, news-driven name like ALT, such tools can help traders spot shifting momentum and manage positions more efficiently than manual chart-watching alone. The signals are designed to surface opportunities, flag weakening trends, and support more disciplined decision-making. Traders interested in complementing fundamental research with systematic, data-driven signals may find AI Daily Buy/Sell Signals a useful addition to their workflow.
Can Altimmune (ALT) stock reach $17? The question is not whether the arithmetic mean of analyst targets points there — it does — but whether the company can convert its clinical pipeline into demonstrable, de-risked value. A roughly 730% move from current levels is a very large ask that would require successful Phase 3 execution, broader indication validation, and sustained investor conviction against formidable competition. The bull case rests on pemvidutide's differentiation and an expanded AUD opportunity; the bear case rests on cash burn, tolerability, and execution risk. With targets ranging from $10 to $28, there is no consensus about magnitude, only broad agreement that the outcome hinges on clinical data. Investors should weigh these factors carefully and monitor upcoming earnings, pipeline updates, and financing developments rather than treating any single price target as a foregone conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALT has been loosely correlated with OGEN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then OGEN could also see price increases.
| Ticker / NAME | Correlation To ALT | 1D Price Change % | ||
|---|---|---|---|---|
| ALT | 100% | +3.92% | ||
| OGEN - ALT | 54% Loosely correlated | +0.51% | ||
| INDP - ALT | 45% Loosely correlated | +1.85% | ||
| FLNA - ALT | 45% Loosely correlated | -3.75% | ||
| DNLI - ALT | 44% Loosely correlated | +7.76% | ||
| EDIT - ALT | 44% Loosely correlated | +4.62% | ||
More | ||||